Main description:

This volume summarizes exciting developments in the therapy of liver disease and not just those using cellular methods New therapies discussed here will include other genetic and gene editing therapies such as CRISPR/Cas9 technology, which is one of the most important new developments in molecular biology. Other topics will include novel stem cell sources of therapeutic cells, bioartificial devices and bioengineered livers for transplantation, and other functioning long-term in preclinical models. New treatments for fibrosis / cirrhosis, which might reverse cirrhosis or reprogram fibroblasts restoring liver function, are reviewed.

Key selling features:

Reviews cell and gene therapies for liver disease

Includes of new methods such as CRISPR technologies

Contributors represent a global team of scientists who originated the research upon which they report

Describes models of liver regeneration

Contents:

Overview of Human Hepatocyte Transplantation. Encapsulated hepatocyte therapy of acute liver failure. Bioartificial liver support for acute liver failure. Recellularized-bioengineered liver tissues for transplantation. Cellular therapies of acute liver failure and fibrosis. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Treatment of end stage cirrhosis by enforced expression of Hepatocyte Nuclear Factor 4. The role of immune cells (or macrophages) in liver disease and regeneration. In vivo reprogramming of myofibroblasts with AAV vectors as a therapeutic strategy for liver fibrosis. Direct reprogramming of hepatic myofibroblasts into hepatocytes, in vivo, attenuates liver fibrosis. In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application. The emerging roles of microvesicles in liver disease and therapy. Amnion epithelial stem cell therapy of metabolic liver disease. Gene therapy for rare metabolic liver diseases. Gene editing technology for the therapy of rare liver diseases.